Is Eli Lilly's Latest Deal a Gamechanger?
One of the biggest contributors to growth in the pharmaceutical industry right now is weight-loss medicine. Diabetes and obesity treatments from Novo Nordisk, such as Ozempic, Rybelsus, and Wegovy, are taking the world by storm.
Eli Lilly (NYSE: LLY) is another rising star in the weight loss arena thanks to blockbuster drug Mounjaro and the company's newest rising star, Zepbound. In late April, Lilly quietly made an acquisition that I think is going to unlock a new phase of growth. The catch? Lilly didn't acquire another company or any rights to competing medications.
Let's break down Lilly's latest move and explore how it should lead to further growth over the long-run.
Source Fool.com
